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Abstract
Genetic tests frequently produce more information than is initially expected. Several 
documents have addressed this issue and offer suggestions regarding how this informa-
tion should be managed and, in particular, concerning the expedience of revealing (or 
not revealing) it to the persons concerned. While the approaches to the management of 
these incidental findings (IFs) vary, it is usually recommended that the information be 
disclosed if there is confirmed clinical utility and the possibility of treatment or preven-
tion. However, this leaves unsolved some fundamental issues such as the different ways 
of interpreting “clinical utility”, countless sources of uncertainty and varying ways of 
defining the notion of “incidental”. Guidelines and other reference documents can offer 
indications to those responsible for managing IFs but should not be allowed to relieve 
researchers and healthcare professionals of their responsibilities.
DEFINITIONS
Recent years have seen steadily mounting interest in 
the issue of “incidental findings” (IFs), their manage-
ment and (possible) disclosure, fuelled partly by the 
convulsive evolution of a wide variety of genetic tests 
and the ensuing increased probability of obtaining un-
expected abnormal results.
So far as large-scale genomics studies are concerned, 
the question of IFs has been debated above all over the 
last ten years, in parallel with an emerging trend within 
the international research community to disclose certain 
single genetic results to research participants [1].
In 2008 Wolf et al. defined IFs as “a finding concern-
ing an individual research participant that has potential 
health or reproductive importance and is discovered in 
the course of conducting research but is beyond the aims 
of the study” [2].
Other similar definitions followed, such as that con-
tained in an important article published five years later, 
which noted that IFs “have been defined as findings hav-
ing potential health or reproductive importance for an 
individual, discovered in the course of conducting a par-
ticular study (in research, clinical care or screening) but 
beyond the aims of that study” [3]. In the same year the 
Public Health Genetics Foundation defined IFs as “ad-
ditional findings concerning a patient or research partici-
pant that may, or may not, have potential health implica-
tions and clinical significance, that are discovered during 
the course of a clinical or research investigation, but are 
beyond the aims of the original test or investigation” [4]. 
Kohane et al. even suggested the term “incidentalomes” 
in the particular setting of medical genomics [5]. The 
term has been adopted by other authors, including Solo-
mon, who used it when proposing an analogy between 
IFs in genomics and in radiology [6]
The earliest definitions of IFs made no clear distinc-
tion between the problems involved in the return of 
unexpected results and those involved in the return of 
research results in general [7]. One of the few exceptions 
was the Statement on the Principled Conduct of Genet-
ics Research of the Human Genome Organisation [8]. 
A distinction between the research and practical settings 
gradually gained usage and has been widely adopted in 
recent articles. The US Presidential Commission for the 
Study of Bioethical Issues (“Bioethics Commission”), 
which had already partially addressed the issue in its 
report “Privacy and progress in whole genome sequenc-
ing” [9] (with particular reference to large-scale genetic 
sequencing), published an ample report entitled “Antici-
pate and communicate: Ethical management of inciden-
tal and secondary findings in the clinical, research, and 
direct-to-consumer contexts” [10], which defined IFs as 
“results that arise that are outside the original purpose 
for which the test or procedure was conducted”. The Bio-
ethics Commission “divides the term ‘incidental finding’ 
into two categories: incidental findings that are ‘antici-
patable’ and those that are ‘unanticipatable’. An antici-
patable IF is a finding that is known to be associated with 
a test or procedure, while an unanticipatable IF includes 
a finding that could not have been anticipated given the 
current state of scientific knowledge”. The Commission 
also draws a distinction between primary, secondary and 
























discovery IFs. Primary findings are results that are active-
ly sought using a test or procedure designed to find that 
result. Secondary findings are those “actively sought by a 
practitioner” but that are not the primary target, and dis-
covery findings are those of a “broad or wide-ranging test 
that was intended to reveal anything of interest” [10].
A BRIEF OVERVIEW
Several influential documents recognise the duty to 
advise participants in research of any information that 
concerns their health. The Council for International Or-
ganizations of Medical Sciences (CIOMS), for instance, 
already in 1991 and again in 2002, in its “International 
Guidelines for Ethical Review of Epidemiological Stud-
ies” recommended that “individual subjects (….) be in-
formed of any finding that relates to their health status” 
[11]. The same guidelines also recognised the subject’s 
“right not to know”. Similar recommendations have been 
issued by the World Health Organisation (WHO) [12]. 
In 2005 the Council of Europe, in Article 27 of the “Ad-
ditional Protocol to the Convention on Human Rights 
and Biomedicine, Concerning Biomedical Research” 
[13, 14], recommended that “If research gives rise to 
information of relevance to the current or future health 
or quality of life of research participants, this informa-
tion must be offered to them. That shall be done within 
a framework of health care or counselling. In comunica-
tion of such information, due care must be taken in order 
to protect confidentiality and to respect any wish of a 
participant not to receive such information”.
The rapid growth of genomic data over the last decade 
has led several national and international groups to draw 
up guidelines on the procedures for informing research 
participants of their individual research results and, in 
particular, of IFs [1]. The report of the US Bioethics 
Commission [10] includes two lengthy appendices of 
lists and brief descriptions of national and international 
reports concerning the issue. The literature also contains 
reviews and summaries of key recommendations [3]. 
These documents often divide IFs into three categories: 
results that must be communicated; results that may be 
communicated; and results that should be withheld.
However, these categories can be interpreted in dif-
ferent ways. There is general consensus that clinically 
useful results should be communicated (but that infor-
mation concerning pathologies for which no treatment is 
currently available and whose disclosure would only give 
rise to apprehension should not be disclosed) [15]. One 
typical approach for communicating research results 
that may serve as an example was adopted in 2004 by a 
working group from the National Heart, Lung and Blood 
Institute (NHLBI) of the National Institutes of Health. 
The group agreed on the conditions that should be met 
for genetic results to be disclosed to research participants 
[16]: briefly, these are that (1) the risk for disease should 
be significant; (2) the disease should have important 
health implications; (3) there should be a proven thera-
peutic or preventative intervention [15].
As we shall see from the broader discussion in the next 
section (“Some of the problems”), the notion of “clinical 
utility” can be interpreted in more than one way. One 
interpretation holds that clinical utility applies to IFs for 
which there exists a potentially useful intervention that 
can improve the individual’s health status [17]. Another 
adopts a broader view and attributes “clinical utility” to 
information that would “facilitate life” [18] and which 
should therefore also be disclosed. Yet other scholars 
propose an even broader approach, holding that IFs 
should always be communicated out of respect for the 
person and regardless of their actionability [19].
These divergent positions are partly due to the differ-
ent ways in which researchers and healthcare profession-
als interpret personal preferences [20]. Some assume a 
paternalistic attitude and consider that certain informa-
tion should be withheld, even when patients would wish 
to know it [21];others attribute a strong normative role 
to subjects’ preferences [22] and believe that all informa-
tion should be disclosed, in accordance with the princi-
ple of respect for the person [23].
Whatever the approach, there is general agreement 
that all due caution should be used in disclosing informa-
tion and that individual circumstances should be taken 
into account, particularly, for instance, when commu-
nicating information concerning minors [24] or genetic 
information that also affects other family members [25].
There is also agreement concerning the crucial role of 
informed consent [26]; it is advisable to include informa-
tion on the procedures for managing eventual IFs in the 
forms submitted to subjects participating in research or 
clinical tests and to acknowledge the right not to be in-
formed, except in specific circumstances [5].
INCIDENTAL FINDINGS: 
SOME OF THE PROBLEMS
Incidental findings pose a number of problems and in-
trinsically present certain weak points. These weaknesses 
are particularly significant when IFs involve genetic data 
derived from screening or other research. The following 
paragraphs mention a few of them.
The distinction between research and current prac-
tice and the notion of “incidental”
The debate over where to draw the line between research 
and current practice has never been satisfactorily resolved 
and the differences of opinion (which date back many 
years, as is evident from the debate shown in the appendi-
ces [27, 28] to the “Belmont Report”  [29]) are still in evi-
dence [30]. One cause of the problem is that the confines 
between the two settings are inevitably blurred [31]. And it 
is not only IFs that are affected; a distinction is crucial, for 
instance, in order to establish the bureaucratic course that 
any procedure should follow. In the case of IFs, however, 
the problem of distinguishing between the two settings is 
particularly delicate because the procedures for their man-
agement may vary according to the specific context. In or-
der to decide whether a particular activity constitutes clini-
cal care or research it may be helpful to refer first of all to 
the underlying motivations. As a general rule, interventions 
in a clinical care setting are personalised, whereas research 
is hypothesis- rather than needs-driven. To establish wheth-
er the setting is one of clinical care or research, it may thus 
be useful to ask whether the rationale for the intervention 
concerns the benefit of the patient or the broader category 
to which the patient belongs [4].
























Yet even the criterion of motivation leaves some issues 
unsolved, as is illustrated by the fact that in 2012 Wolf et 
al. [18] re-considered the notion of IFs that some of them 
had proposed four years earlier [2]. The authors recognised 
that while the expression “IFs” was appropriate in the con-
text of genetics research procedures that had in the mean-
time become obsolete, it is not always appropriate where 
more advanced techniques are being used, particularly 
genome screening. They consequently acknowledged that 
the expression itself may hamper the process of agreeing 
an unambiguous definition of the circumstances in which 
researchers are duty-bound to disclose their findings to re-
search participants. They noted that “in large-scale discov-
ery research (…) it is difficult to identify what is ‘beyond 
the aims of the study’ because the entire genome is under 
scrutiny and the research is inductive discovery research 
rather than research driven by discrete hypotheses” [18]. 
Despite these misgivings the authors maintained that the 
expression “IFs” was still valid, and provided examples to 
support their position. One example is the case of a genom-
ics researcher who, during the enrolment phase of a study, 
discovers that a potential participant has elevated blood 
pressure. Wolf et al. proposed distinguishing IFs from what 
they call “individual research results”, i.e. a finding “discov-
ered in the course of the research, when the finding is on 
the focal variables under study in meeting the stated aims 
of the study” [18]. This distinction thus focuses on the in-
tentions: if the researcher was not looking for the find-
ing, then it is an incidental finding; if, on the other hand, 
the researcher was looking for it, then it is an individual 
research result. This brings us back to the distinction 
between research and clinical practice mentioned ear-
lier. Even if it were possible to make a clear distinction 
between the two settings, the fact remains that the mo-
tivation (focusing on the patient or even embracing the 
broader category to which the patient belongs) does not 
help to decide how to manage the results: “If research-
ers are obliged to return data indicating the presence of 
a mutation that markedly increases the risk of disease, 
that duty applies whenever such information is in their 
hands, whether they intended to find it or not. Unfor-
tunately, however, the complicated conversation about 
which results to return to subjects risks becoming still 
more complicated if we use a term that gives unwar-
ranted attention to just that: the researcher’s original 
intention” [32]. To address this problem Parens et al. 
“suggest ‘individual genomic result’. The term avoids the 
problem of giving undue attention to the researcher’s 
or clinician’s intentions. To the extent that the term is 
vague, the vagueness may be a virtue. It reminds us of 
the real, difficult work that remains: articulating criteria 
to distinguish between individual genomic results that 
do – and do not – warrant an offer to return to research 
participants or  patients” [32]. In the case of genome 
screening, the already difficult search for an appropriate 
term is compounded by the fact that it is difficult “to 
identify what might be an [incidental finding], as any 
genomic pattern correlating with pathology may be cap-
tured and studied” [32]. Thus the notion of “incidental” 
remains controversial [33] “It could be said that nearly 
nothing is ‘incidental’ because very little is outside the 
scope of the research question” [34].
Clinical utility
Recommendations often refer to notions or concepts 
without offering a precise definition of them. This may 
give rise to difficulties, whether the notion is a broad one 
(such as “health status”) or more specific (such as “reli-
able” or “potential benefit”), and the interpretations of 
these concepts are left to professional judgment.
As noted above, one of the notions that, in the absence 
of clear definitions, lends itself to subjective interpreta-
tions is the term “clinical utility”: the term “actionability” 
is similarly problematic. Yet some documents consider 
these concepts to be crucial when it comes to deciding 
the procedures for managing IFs. The margins of sub-
jectivity for interpreting “utility” are also to be found in 
guidelines concerned mostly with practical aspects. For 
instance, a document published by the Public Health 
Genetics Foundation, which takes a very pragmatic ap-
proach, recommends that the “100 000 Genomes Pro-
ject” (100kGP) “should adopt a policy of disclosing only 
research findings that are scientifically significant and 
have been assessed by a competent individual that are 
clinically significant AND severely or moderately life 
threatening AND clinically actionable. The operationali-
zation of these terms will need to be determined for in-
dividual research projects. The consent procedure should 
also include a description of what types of findings will 
be disclosed, why these and not others; and also that any 
findings disclosed from research studies may need to 
be validated in a clinical laboratory” [4] (author’s note: 
capitalised in the original). In the absence of an accepted 
interpretation of “actionability” this recommendation is 
subject to a number of interpretations (particularly if the 
concepts  of “life threatening” and “clinically actionable” 
are applied to pathologies rather than findings!).
Pleiotropy
It is often pointed out that reliable information and 
data management systems need to be established that 
clearly identify the risks associated with each genetic 
variant included in research studies [35]. One of the rea-
sons for the difficulty of positively identifying these risks 
is pleiotropy, a factor that is insufficiently addressed in 
several of the guidelines and recommendations concern-
ing IFs. Pleiotropy – or the phenomenon of a single gene 
or genetic variant affecting multiple phenotypes – can 
considerably complicate the decision as to whether or 
not to disclose a finding.
The ε4 variant of the APOE gene may be associated 
with a (treatable) cardiovascular risk and with a risk of 
developing (untreatable) Alzheimer’s disease [36]. The 
recommendations included in some guidelines are that 
information regarding the former risk be disclosed and 
information regarding the latter withheld. This poses 
problems for both the researcher and the clinician who 
must disclose the information [37].
The question of pleiotropy arises fairly frequently in 
the management of IFs. One significant example of this 
is the list of 57 genes for which the American College of 
Medical Genetics and Genomics (ACMG) believes that 
incidental findings should be sought and reported in clin-
ical exome and genome sequencing [38]. As Kocarnick 
and Fullerton observed in the Online Mendelian Inherit-
























ance in Man resource, 43 of these 57 genes have multiple 
associated phenotypes listed: thus, even if the disclosure 
of IFs is limited only to the genes identified in carefully 
chosen lists, considerable problems still remain [39].
IFs, uncertainty, the problems for researchers: some 
general considerations
One of the key problems in the management of IFs 
is the uncertainty that surrounds them. This uncertainty 
can be associated with a number of factors: it is particu-
larly important in the early stages of research and in the 
genetics setting, where most disease predictions based 
on genetics are probability estimates [35] and the sig-
nificance of IFs may vary between ethnic groups [5]. The 
uncertainty factor in IFs is further compounded by the 
fact that they are generally unconfirmed.
This uncertainty is one of the key elements complicat-
ing the task of researchers when managing IFs, to the 
extent that “most genetics researchers, while aware of 
the potential for incidental findings, simply do not want 
to deal with them” [34]. This reluctance has been rec-
ognised in several documents. Even before the expres-
sion “incidental findings” became established, both the 
American Society of Human Genetics [40] and the 
Canadian College of Medical Geneticists [41] acknowl-
edged that researchers have limited expertise in handling 
medically relevant information and recommended that 
the results of DNA tests should first be communicated 
to an appropriate healthcare professional, who in turn 
can decide whether or not to disclose the information to 
the individual concerned. Other documents recommend 
that researchers should be trained specifically to man-
age IFs and that their training should cover not only the 
technical aspects but also the procedures for dealing with 
them. This points to a need: the various documents – 
and guidelines, in particular – undoubtedly provide fun-
damental guidance for the management of IFs, but they 
cannot replace the individual responsibility of research-
ers and healthcare professionals, who must consider each 
case on its merits, bearing in mind the peculiar circum-
stances of each individual [42, 43].
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